Overview of Zydol SR

Property	Description
Active ingredient	Tramadol Hydrochloride
Form	Sustained Release Tablet (SR)
Pharmacological class	Central Acting Analgesic, Opioid Analgesic
Common use (General)	Management of moderate to moderately severe pain
Origin	Synthetic compound

What is the Core Identity of Zydol SR?

Zydol SR is a specialized synthetic, prescription-only medicine defined by its active ingredient, Tramadol Hydrochloride, a parent compound used for pain relief. The substance is officially classified as an opioid analgesic, belonging to a group of agents that modulate pain signals within the central nervous system. Its specific Sustained Release Tablet form sets it apart from immediate-release Tramadol products.

This single-ingredient oral medication is a member of the class of centrally acting analgesics, meaning its primary therapeutic effect is exerted within the brain and spinal cord, rather than the site of injury. The compound is used in addressing persistent pain.

How is Zydol SR Classified?

Zydol SR is formally classified as a Central Acting Analgesic that achieves its pain-relieving effect through a dual mechanism of action, a key differentiating feature from traditional single-pathway opioids. The pharmacological class involves binding to the mu-opioid receptor, but the compound also inhibits the reuptake of the neurotransmitters serotonin and norepinephrine. This medication modulates pain through both opioid and monoaminergic pathways.

This dual functionality relates to chronic pain management, as it targets multiple pathways for analgesic efficacy. The medication is therefore used for the general purpose of managing moderate to moderately severe pain where consistent, stable relief is necessary.

What Does the “SR” Formulation Mean?

The “SR” in Zydol SR signifies a Sustained Release Tablet, classifying it as an Extended Release Formulation designed for gradual, controlled delivery of the active ingredient. This specialized Oral Dosage Form ensures the medication's effect is maintained over an extended period.

The Sustained Release design is intended for adult patients, as it prevents fluctuations in drug concentration often associated with immediate-release forms, providing prolonged action. This delivery mechanism supports continuous pain relief, offering a stable therapeutic presence that addresses the persistent nature of chronic pain.

What side effects are possible with Zydol SR?

Possible Side Effects and Safety Information

The safety profile of Zydol SR, which contains Tramadol Hydrochloride, is defined by regulatory documents that classify potential adverse effects based on frequency, physiological system, and seriousness. All documented statements strictly reflect official regulatory information, without containing clinical advice or usage instructions.

Frequency-Classified Adverse Reactions

The most frequently reported effects primarily involve the gastrointestinal and nervous systems:

Very Common (affecting more than 1 in 10 individuals): Nausea, Dizziness, Somnolence (drowsiness), Constipation, and Headache are typically classified at this level.
Common (affecting 1 in 10 to 1 in 100 individuals): Reactions include Vomiting, Dry Mouth, Sweating (hyperhidrosis), and Fatigue.

Less common events include anomalies in cardiovascular regulation, such as postural hypotension and palpitations, as documented in the Uncommon frequency tier.

Serious Adverse Reactions and Safety Constraints

Official labeling mandates specific warnings regarding rare but clinically significant risks. The serious risks highlighted include Life-Threatening Respiratory Depression and the potential for Serotonin Syndrome due to the drug’s pharmacological characteristics. Seizures (convulsions) are also listed as a potential risk. These serious effects are closely monitored, particularly during the initiation of therapy or following a dose increase.

The regulatory profile also includes constraints for specific populations. The drug is contraindicated in children younger than 12 years of age. Furthermore, caution and potential dosage adjustment are noted for patients with significant renal or hepatic impairment due to altered drug clearance. The risk of dependence, abuse, and misuse is associated with prolonged use.

Overdose and Emergency Response

Overdose and when to seek help

Element	Official Regulatory Documentation Statement
Documented Overdose Presentations	CNS depression progressing to coma, respiratory depression, seizures, miosis, hypotension, and circulatory collapse
Physiological Systems Affected	Central Nervous System, Respiratory System, Cardiovascular System
Population-specific Overdose Notes	Accidental ingestion in children can be fatal. Life-threatening respiratory depression has occurred in children and in elderly or debilitated patients
Emergency-response statements	Symptomatic and supportive treatment is the primary approach. Naloxone is used for respiratory depression, but it may increase seizure risk
When immediate medical help is required	Seek immediate medical attention for any suspected overdose; urgent hospitalization is required

Overdose Classifications (High-Level)

Classification Type	Official Regulatory Documentation Statement
Severity classification	Described as potentially life-threatening or fatal due to risk of respiratory arrest
Overdose-context constraints	Haemodialysis is generally not suitable for detoxification

Resulting Overdose Structure Official overdose statements:

The condition involves critical risks such as respiratory arrest, cardiac arrest, and circulatory collapse.
Intensive care monitoring and close observation of respiratory and cardiovascular function are mandated.

Connection to the overall overdose profile Government regulatory documents define this overdose profile by the severe, acute risks to the respiratory and central nervous systems, which necessitate prompt contact with emergency services. This classification requires immediate supportive care and monitoring, using Naloxone as the specified intervention for respiratory compromise, with documented limitations against non-opioid manifestations like seizures.

Therapeutic Uses of Zydol SR

What Zydol SR Treats: Main Uses and Benefits

Zydol SR is generally considered relevant for providing stable, consistent relief in situations involving persistent, moderate to moderately severe pain. The extended-release forms may be part of symptomatic management when a patient requires around-the-clock assistance for an extended period. This supports the management of discomfort associated with chronic conditions.

It is commonly used in the symptomatic relief of conditions presenting with systemic or localized discomfort, including those linked to conditions such as osteoarthritis and chronic low back pain. It is applied in addressing symptoms that interfere with daily functioning and is considered relevant for pain that has been refractory or insufficiently managed by first-line non-opioid pain relievers.

“The Sustained Release formulation is relevant in contexts involving persistent discomfort that may require additional symptomatic support.”

This approach contributes to easing the overall symptom load and assists with maintaining functional stability during periods of heightened symptoms.

Quick Fact: Relief for Persistent Pain
Primary Focus: Managing chronic pain syndromes and conditions marked by ongoing, moderate to moderately severe somatic discomfort.
Key Benefit: Supports around-the-clock comfort and may assist with maintaining functional stability during symptom fluctuations.

Regulatory References

NIH MedlinePlus overview of Tramadol

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Zydol SR

Official regulatory documents strictly define the population eligibility for Zydol SR (Tramadol SR) across several domains, establishing absolute prohibitions, restrictions, and conditional use based on patient health status and age.

Eligibility Scope

Classification	Population or Condition	Regulatory Status
Contraindicated	Children younger than 12 years of age	Prohibited
Contraindicated	Children under 18 years post-tonsillectomy/adenoidectomy	Prohibited
Contraindicated	Patients with significant respiratory depression or acute/severe bronchial asthma	Prohibited
Contraindicated	Patients taking MAO Inhibitors (or within 14 days of use)	Prohibited
Not Recommended	Patients with severe hepatic or severe renal impairment	Avoided
Not Recommended	Pregnancy or Lactation (due to risk of NOWS/infant adverse effects)	Avoided
Restricted Use	Adolescents 12 to 18 years with respiratory risk factors	Avoided/Cautioned
Restricted Use	Patients with a history of epilepsy or seizure susceptibility	Use with Caution
Restricted Use	Patients over 75 years of age	Use with Caution

Official Eligibility Statements

The medicine is contraindicated for patients with known hypersensitivity to tramadol or any excipients, and in states of acute intoxication with central nervous system depressants.
Use is prohibited in all children younger than 12 years and is strongly restricted for those younger than 18 years following tonsillectomy or adenoidectomy.
The drug is not recommended for use in patients with severe impairment of kidney or liver function due to delayed drug elimination.
Use during pregnancy and lactation is not recommended by regulatory bodies.

What should I know about interactions with other medicines?

Zydol SR’s interaction profile is strictly defined by regulatory documents, focusing on pharmacodynamic risks and metabolic changes. Formal Contraindications documented in official labeling include co-administration with Monoamine Oxidase Inhibitors (MAOIs). This combination necessitates a mandatory 14-day separation period between discontinuing the MAOI and initiating Zydol SR to manage the risk of Serotonin Syndrome. Co-administration with other tramadol-containing products is also prohibited.

The official label warns against combining Zydol SR with Central Nervous System (CNS) depressants, including alcohol, due to a potentiation of effects resulting in a serious risk of profound sedation and respiratory depression. Co-administration with other serotonergic agents or medicines that lower the seizure threshold may increase the respective documented risks.

From a pharmacokinetic perspective, interactions involve the CYP450 enzyme system. Drugs that inhibit CYP2D6 or CYP3A4 may increase the plasma concentration of Tramadol while decreasing the level of its active metabolite (M1). Conversely, CYP3A4 inducers such as Carbamazepine are documented to reduce the analgesic effect by increasing the speed of metabolism, a use generally not recommended. The official label also notes a specific population consideration, cautioning against use in CYP2D6 Ultra-Rapid Metabolizers due to the potential for fatal respiratory depression.

Mechanism of Action

Zydol SR exerts its action through a dual mechanistic pathway involving both opioid and monoaminergic systems. The compound acts as an agonist primarily at the mu-opioid receptor (mu-OR) within the central nervous system, particularly in the brain and spinal cord. Binding to the mu-OR initiates intracellular G-protein-coupled signaling cascades, which results in the inhibition of adenylate cyclase and the modulation of ion channel conductance (specifically promoting potassium efflux and inhibiting calcium influx). This cellular process leads to the hyperpolarization of the neuronal cell membrane, thereby decreasing nerve cell excitability and reducing presynaptic neurotransmitter release.

Simultaneously, the compound acts as an inhibitor of the neuronal reuptake of two key monoamine neurotransmitters: norepinephrine (NE) and serotonin (5-HT). By preventing the clearance of these neurotransmitters from the synaptic cleft, Zydol SR enhances the activity of the descending inhibitory pathways. The combined effect of mu-OR agonism and monoamine reuptake inhibition leads to the system-level modulation of nociceptive signal transmission.

Dosage and Administration Information

Zydol SR is a prolonged-release tablet formulation intended for oral administration only. The tablets must be swallowed whole with sufficient liquid and must not be cut, crushed, chewed, or dissolved. Altering the tablet structure prevents the controlled, sustained release of the active ingredient, which is central to its usage pattern.

The standard adult usage pattern involves a twice-daily administration schedule, typically taken in the morning and evening to maintain continuous drug levels. The usual initial dose is 50 mg to 100 mg per dose. The total dose is adjusted based on individual need, and the maximum recommended daily intake for the prolonged-release formulation generally should not exceed 400 mg, although some guidelines specify a maximum of 300 mg per day. The tablets can be taken independent of meals, but standard instructions suggest maintaining a consistent approach (e.g., always with food or always without).

This medicine is prescribed for around-the-clock pain treatment and is not intended for as-needed use. For specific populations, the administration schedule may require modification: Zydol SR is not suitable for children under 12 years of age. In older patients (over 75 years) or those with certain hepatic or renal impairments, standard protocols involve the dosage interval to be extended due to potential changes in the medicine’s elimination. If treatment is no longer required, the dosage must be tapered gradually rather than stopped abruptly.

Recent Clinical Evidence

Research evidence / Overview of studies for Zydol SR

This overview describes the research landscape for Zydol SR (Sustained Release Tramadol), focusing on the types of studies that have been conducted, the outcomes they measured, and areas where more research is still needed, according to official regulatory and scientific sources. The findings describe group patterns, not personal outcomes.

Evidence for use in Chronic, Non-Malignant Pain

Research exploring Zydol SR was studied for use in chronic pain characterized by moderate to moderately severe discomfort and has primarily relied on short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and compared the sustained-release formulation to a placebo to see how symptoms changed over defined time intervals. The outcomes studied included patient-reported changes in pain intensity and outcomes reflecting daily functioning.

Studies reported measurements of pain scores and functional outcomes across the study period, including comparisons to the placebo group. Long-term outcomes regarding the sustained measurements of pain and functional status are not fully established by the short-term RCTs. Evidence derived from these settings has been noted to be heterogeneous, meaning findings were mixed across the different types of chronic pain syndromes that were included.

Evidence for use in Osteoarthritis Pain

Zydol SR was studied for its role in conditions characterized by functional limitations, specifically osteoarthritis of the hip or knee. Short-term, placebo-controlled RCTs explored measurements of patient-reported outcomes describing perceived discomfort, including specific functional scales like the WOMAC index.

The findings indicate that the clinical trials reported changes in the measured outcomes related to pain and functional scores when comparing the study group to the placebo group over the short term. The major limitation here is that the follow-up durations were limited, confining the understanding of long-term outcomes beyond the trial window.

What Is Still Uncertain About Zydol SR Evidence

Official scientific reviews highlight several areas where evidence is limited or where research is ongoing. The overall certainty of evidence for minimal clinically important difference in pain reduction is often described as low or moderate. Comparative evidence is lacking for several alternative sustained-release pain formulations. Furthermore, while the medication was observed in trials exploring short-term symptom changes, the long-term effects are not fully established regarding functional status and the overall progression of chronic pain conditions.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Zydol SR (FAQ)

Q: Why does Zydol SR come in different strengths?

According to official product information, Zydol SR is available in different strengths to allow for individual dose adjustment. This flexibility is necessary so that a healthcare professional can tailor the medicine's dosage based on the severity of the patient's pain and how they respond to the treatment.

Q: Are there any common over-the-counter medicines that should be avoided while taking Zydol SR?

Official warnings advise caution when taking Zydol SR with certain other medicines. This includes being advised to avoid taking it with codeine-containing painkillers (such as co-codamol or Nurofen Plus) that can be bought over-the-counter. Combining these agents increases the risk of certain side effects.

Q: Can Zydol SR affect sleep quality?

Official safety documents list two potentially opposing effects related to sleep. The medicine's adverse reaction profile commonly includes both somnolence (a feeling of drowsiness) and insomnia (difficulty falling or staying asleep).

Q: Are there long-term safety concerns associated with taking Zydol SR?

Regulatory documents emphasize that long-term use requires regular monitoring by a healthcare professional to assess the continuing necessity of the treatment. Potential concerns documented include the development of tolerance and physical/psychological dependence (known as Opioid Use Disorder). Chronic use has also been linked to potential effects on the hormonal system, which may relate to infertility.

Q: Do food or dairy products affect how Zydol SR is absorbed?

Clinical studies confirm that food intake does not appear to affect the bioavailability (absorption) of the active ingredient. Therefore, the official instructions permit the tablets to be taken independent of meals.

Q: Is Zydol SR the same as Tramadol?

Tramadol Hydrochloride is the active ingredient contained in Zydol SR. The key difference is the formulation. Zydol SR is a Sustained Release tablet, meaning it is designed to deliver the medicine gradually over a longer period to provide continuous pain relief, unlike immediate-release forms of Tramadol.

Q: How long does the effect of one dose of Zydol SR usually last?

The Sustained Release design is intended for prolonged action and to support continuous pain relief. Official product information indicates the effects generally last for a sustained duration, supporting a once-daily or twice-daily dosing regimen.

Q: Can Zydol SR cause mood changes or depression?

Official documents state that mood changes can be a possible symptom of a serious, rare side effect called Serotonin Syndrome. While the medicine is used with caution in patients with existing mental health disorders, depression is not listed as a common or very common adverse effect in the official safety profile.

Q: Is Zydol SR effective for nerve pain (neuropathic pain)?

The medicine works via a dual mechanism of action that modulates pathways relevant to nerve signaling. Regulatory documents have noted its use in combination with certain other medicines (such as gabapentin or pregabalin) for the management of pain due to nerve problems (neuropathic pain).

Q: Does Zydol SR have anti-inflammatory effects?

Official regulatory documents describe the medicine's primary action as a centrally acting analgesic. Its mechanism involves affecting the opioid and monoaminergic systems. It does not have a stated anti-inflammatory mechanism of action described in official product information.

Q: How long does it typically take for Zydol SR to start working?

Because Zydol SR is a sustained-release formulation designed to provide a steady effect over a long period, it may take longer to feel the start of the pain-relieving effects when compared to immediate-release forms of the medicine.

Q: What should I do if I miss a dose of Zydol SR?

Official patient information describes the recommended approach for a missed dose: taking the dose as soon as it is remembered, unless the time for the next dose is due within a few hours. The instructions explicitly state that taking a double dose to make up for a forgotten one is not recommended.

Q: Does taking Zydol SR impact driving ability?

Official warnings state that the medicine may cause side effects such as dizziness and drowsiness (somnolence). Official warnings state that, if affected by these symptoms or any other effects that could impair their ability to safely perform such tasks, it is not recommended to drive or operate machinery.

Q: Does Zydol SR interact with herbal supplements?

Regulatory documents advise caution when considering co-administration with herbal remedies and supplements. The safety of taking them with Zydol SR has not been established in the same clinical trials as prescription medicines, due to differences in testing and regulation.

Q: Can Zydol SR be used while breastfeeding?

Official product information states that the active ingredient passes into breast milk in very small amounts. While side effects are considered unlikely in a healthy baby, official product information indicates that consultation with a healthcare professional is recommended to confirm if use is appropriate while breastfeeding, especially for long-term treatment.

Q: Can Zydol SR be used while pregnant?

The medicine is not usually recommended during pregnancy due to insufficient safety evidence. Official warnings emphasize that prolonged use of the active ingredient at the end of a pregnancy can cause a serious condition in the baby called neonatal opioid withdrawal syndrome (NOWS).

Q: Is Zydol SR restricted or controlled in some countries?

Yes, the active ingredient is classified as a Schedule IV controlled substance in the United States by the Drug Enforcement Administration (DEA). This classification places specific legal restrictions on how the medicine is prescribed, dispensed, and refilled.

Q: Does Zydol SR show up on a standard drug test?

The active ingredient, Tramadol, is not always included in the most basic, standard drug screening tests. Detection may require a specific or extended opioid panel test to be performed.

Q: What is the maximum duration of treatment with Zydol SR mentioned in official guidelines?

Official guidelines do not specify a maximum duration for treatment. However, regulatory documents state that if long-term treatment is necessary, it should be subject to careful and regular monitoring to confirm the continuing therapeutic need.

Q: Why is Zydol SR sometimes used with other pain relievers?

The medicine is sometimes used concurrently with non-opioid analgesics, such as paracetamol or ibuprofen. This co-administration is noted in patient information to provide additional pain relief when alternative treatments alone have not been fully effective.

Q: Does Zydol SR interact with blood thinners?

Yes, official warnings advise caution when taking Zydol SR with certain coumarin anticoagulants (often called blood thinners), such as warfarin. This interaction has been noted to potentially affect blood clotting levels and increase the risk of bleeding.

Q: Is there a generic version of Zydol SR available?

Yes, the active ingredient in Zydol SR, Tramadol Hydrochloride, is available in generic formulations. These include generic versions of extended-release tablets.

Q: Does Zydol SR have a 'black box' warning?

Yes, the active ingredient in the extended-release formulation carries an FDA Boxed Warning, which is the highest level of caution. This warning highlights serious risks, including addiction, abuse, and misuse, life-threatening respiratory depression, and the potential for Neonatal Opioid Withdrawal Syndrome.

Q: Can Zydol SR affect fertility?

Chronic use of the active ingredient may influence the hypothalamic-pituitary-gonadal axis, which is the body's hormonal system. This effect has been linked to potential issues like infertility and may affect the menstrual cycle in women.

Q: What is the half-life of Zydol SR's active ingredient?

The active ingredient, Tramadol, has a half-life of approximately 6 to 8 hours. The specific Sustained Release formulation is engineered to leverage this half-life to provide a more consistent drug level over the entire dosing interval.

Q: Does Zydol SR lose effectiveness over time (tolerance)?

Yes, official product documents state that tolerance may develop with repeated and long-term use of the medicine. Due to this potential for reduced effectiveness, the clinical need for continued treatment should be regularly reviewed by a healthcare professional.

How should Zydol SR be stored and disposed of?

Storage and Disposal of Zydol SR

Zydol SR prolonged-release tablets must be stored securely according to official labeling. The medicine must be kept out of the sight and reach of children to prevent fatal accidental ingestion of this opioid analgesic.

Storage Requirements

Store the tablets below 30°C (86 F) and protect them from light. The medication should remain in the original pack (blister) until the time of use and must not be used after the expiry date.

Disposal Instructions

Unused or expired Zydol SR must not be disposed of via wastewater or household waste. Disposal must be completed in accordance with local requirements. Patients should consult a pharmacist for guidance or utilize available drug take-back programs.

Zydol SR